Shimizu M, Fujii H, Mizoguchi H, Masuda M, Toyama K, Yoshikawa O, Kawanishi K, Fujimaki M, Arai M, Handa M
Department of Transfusion Medicine, Tokyo Women's Medical College.
Rinsho Ketsueki. 1992 Feb;33(2):148-56.
The clinical safety and efficacy of transfusion of red cell concentrates stored in MAP solution (MAP-CRC) containing mannitol, adenine, glucose, phosphate and citrate, into 39 anemic patients were evaluated. In 23 patients, infusion of MAP-CRC was alternated with infusion of ordinary CRC as a control. The MAP-CRC and CRC used in this study were stored at 4 degrees C for an average of 38.2 +/- 2.6 days (n = 52) and 18.1 +/- 2.2 days (n = 26), respectively. Red cell recovery was 77.5% for MAP-CRC and 82.5% for CRC, based on calculation of the increase in hemoglobin level one day after transfusion. There were no differences between patients transfused with MAP-CRC and those transfused with CRC in clinical findings or biochemical data. No major side-effects other than pyrexia associated with the underlying infections were seen in patients transfused with MAP-CRC. MAP-CRC stored up to 42 days is apparently as safe and effective as stored CRC. This new additive solution may therefore be useful for the future expansion of the indications for autologous blood transfusion by facilitating the collection and storage of more blood in the liquid state for a longer period, and may also be useful in obtaining more plasma from whole blood as source plasma.
对39例贫血患者输注含有甘露醇、腺嘌呤、葡萄糖、磷酸盐和柠檬酸盐的MAP溶液保存的红细胞浓缩液（MAP-CRC）的临床安全性和有效性进行了评估。在23例患者中，输注MAP-CRC与输注普通红细胞浓缩液（CRC）作为对照交替进行。本研究中使用的MAP-CRC和CRC分别在4℃下平均保存38.2±2.6天（n = 52）和18.1±2.2天（n = 26）。根据输血后一天血红蛋白水平的升高计算，MAP-CRC的红细胞回收率为77.5%，CRC为82.5%。输注MAP-CRC的患者与输注CRC的患者在临床发现或生化数据方面没有差异。输注MAP-CRC的患者除了与潜在感染相关的发热外，未观察到其他主要副作用。保存长达42天的MAP-CRC显然与保存的CRC一样安全有效。因此，这种新的添加剂溶液可能有助于通过促进更多液态血液的收集和更长时间的保存来扩大自体输血的适应症，也可能有助于从全血中获得更多血浆作为源血浆。
